Digital image of WuXi Biologics' Ireland facility (via presentation from WuXi Biologics)
December 4, 2023 07:02 AM ESTUpdated 05:11 PM
Manufacturing

WuXi Bi­o­log­ics’ stock slides 24% as man­u­fac­tur­ing busi­ness slows amid biotech down­turn

Anna Brown

News Reporter

WuXi Bi­o­log­ics stock has plum­met­ed 24% to the low­est it’s been this year af­ter the Hong Kong stock ex­change closed Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times